Texas Attorney General Ken Paxton has launched a landmark lawsuit against Tylenol makers Johnson & Johnson and Kenvue, alleging deceptive marketing to pregnant women and a concealed link between acetaminophen and autism, setting off a fierce debate between legal claims and prevailing medical consensus.
The state of Texas has opened a new front in the ongoing national debate surrounding the safety of Tylenol (acetaminophen) during pregnancy. On October 28, 2025, Texas Attorney General Ken Paxton filed a lawsuit against pharmaceutical giants Johnson & Johnson and Kenvue, accusing them of knowingly concealing the risks of acetaminophen to unborn children and deceptively marketing the drug as safe for pregnant women. This legal action escalates a controversy that gained significant public attention after recent statements from the Trump administration linking the pain reliever to neurodevelopmental disorders.
The Core Allegations: Deceptive Marketing and Hidden Dangers
The lawsuit, filed in the District Court of Panola County, is a serious challenge to the long-standing perception of Tylenol as a benign painkiller for expectant mothers. Paxton’s complaint asserts that Johnson & Johnson and Kenvue, which spun off from J&J in 2023, knew for decades that acetaminophen could be dangerous to unborn and young children. Despite this alleged knowledge, the companies are accused of hiding the danger and aggressively marketing Tylenol as “the only safe painkiller for pregnant women.”
The specific claims within the lawsuit include:
- Violation of Texas’ deceptive trade practices act by promoting Tylenol while concealing risks.
- Allegations that acetaminophen use during pregnancy and early childhood causes conditions such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD).
- Accusations that Johnson & Johnson attempted to shield its assets from potential lawsuits by transferring Tylenol-related liabilities to Kenvue, thereby violating the Texas Uniform Fraudulent Transfer Act.
Paxton emphasized the broader implications of the suit, stating, “Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks. These corporations lied for decades, knowingly endangering millions to line their pockets.” The lawsuit seeks civil penalties of up to $10,000 per violation and requests the destruction of marketing materials suggesting the drug’s safety for pregnant women.
The Trump Administration’s Influence
The Texas lawsuit arrives just a month after the Trump administration publicly issued a controversial warning about acetaminophen. In September, President Donald Trump, alongside Health and Human Services Secretary Robert F. Kennedy Jr., announced that the FDA would immediately notify physicians that “the use of acetaminophen during pregnancy can be associated with a very increased risk of autism.” Kennedy cited studies suggesting a “potential association” between prenatal acetaminophen use and adverse neurodevelopmental outcomes, referencing research in journals like Environmental Health.
This federal pronouncement significantly amplified public concern and likely provided impetus for state-level actions like the Texas lawsuit. Paxton explicitly referenced the Trump administration’s claims in his filing, stating that the “federal government confirmed what defendants knew for years.”
The Medical Community’s Firm Rebuttal
Despite the legal and political claims, the prevailing consensus among top medical experts and organizations stands in stark contrast to the assertions of a definitive link between acetaminophen and autism. Major health organizations have consistently stressed that scientific evidence does not support such concerns, and they continue to endorse acetaminophen as a safe and crucial option for pregnant patients.
The American College of Obstetricians and Gynecologists (ACOG), for instance, stated, “there is no clear evidence that proves a direct relationship between the prudent use of acetaminophen during pregnancy and fetal developmental issues.” This position is echoed by groups such as the Society for Maternal-Fetal Medicine and the American Academy of Pediatrics (AAP). Dr. Steven J. Fleischman, president of ACOG, called suggestions of a causal link “irresponsible,” highlighting that acetaminophen is one of the few safe options available for treating conditions like fever and pain, which, if left untreated, can pose significant risks to both mother and baby, as discussed in numerous medical journals including studies published in JAMA.
These medical bodies underscore the critical role of acetaminophen in managing common ailments during pregnancy. They warn that misinformation regarding its safety could lead pregnant women to forgo necessary treatment, potentially exposing them to greater health risks from untreated fevers or severe pain.
Kenvue and Johnson & Johnson’s Vigorous Defense
Both Kenvue and Johnson & Johnson have vehemently denied the allegations. Kenvue, as the current maker of Tylenol, issued a strong statement asserting that Texas’ claims “lack legal merit and scientific support.” The company vowed to “vigorously defend” itself in litigation, reiterating that acetaminophen “is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy.”
Kenvue also expressed deep concern over “the perpetuation of misinformation on the safety of acetaminophen and the potential impact that could have on the health of American women and children.” They argue that denying pregnant women access to acetaminophen could force them to endure dangerous conditions or resort to riskier alternatives, emphasizing that “high fevers and pain are widely recognized as potential risks to a pregnancy if left untreated.” The company detailed its position in an official statement responding to the Texas Attorney General’s action.
For its part, Johnson & Johnson clarified its limited involvement, stating that it “divested its consumer health business years ago, and all rights and liabilities associated with the sale of its over-the-counter products, including Tylenol (acetaminophen), are owned by Kenvue.” This statement aligns with Paxton’s accusation regarding the transfer of liabilities, though J&J’s perspective frames it as a legitimate business separation rather than an attempt to evade responsibility.
Broader Implications and the Path Forward
The Texas lawsuit marks a significant development, being the first of its kind from a state government against Tylenol manufacturers regarding autism claims. It places a spotlight on the intersection of public health, pharmaceutical marketing, political influence, and legal accountability. The outcome could set precedents for similar cases and potentially reshape how over-the-counter medications are marketed and perceived, especially for vulnerable populations like pregnant women.
For consumers, the conflicting information from government warnings, medical experts, and legal challenges can be confusing and alarming. The debate highlights the importance of relying on established medical advice and the potential dangers of unsubstantiated claims impacting public health decisions. As this high-stakes legal battle unfolds, the focus will remain on the scientific evidence (or lack thereof) supporting the alleged link between acetaminophen and neurodevelopmental conditions, and the extent to which pharmaceutical companies can be held accountable for their marketing practices.
